BD and Biosero Partnership Enhances Drug Discovery Automation
BD and Biosero Partnership for Enhanced Drug Discovery
BD (Becton, Dickinson and Company) (NYSE: BDX), a leader in medical technology, has joined forces with Biosero, a pioneer in laboratory automation, to establish a groundbreaking collaboration. This partnership aims to integrate robotic automation with BD's flow cytometry instruments to streamline the drug discovery and development process.
Innovative Software Capabilities
In this partnership, the focus will be on developing advanced software capabilities that allow BD flow cytometry instruments to work seamlessly with Biosero’s Green Button Go® software. This integration aims to support biopharmaceutical companies and contract research organizations in their specific research requirements, enabling smoother operations with robotic platforms.
Automation Benefits
Currently, many steps involved in laboratory flow cytometry workflows are performed manually, a process that can be time-consuming and prone to human error. By implementing robotic arms, labs can automate these steps, allowing for higher throughput and efficiency. For instance, instead of manually changing multiwell plates for analysis—typically done one at a time—robots can efficiently manage multiple plates, significantly reducing operational time.
The Role of Flow Cytometry in Drug Development
Flow cytometry is a crucial technology in drug discovery, providing insights by analyzing the effects of drug candidates on single cells within diverse populations. It also plays a vital role in cell therapy manufacturing by ensuring the safety and efficacy of the therapeutic products through continuous monitoring and analysis of cells.
Boosting Laboratory Productivity
As noted by Ryan Bernhardt, CEO of Biosero, their laboratory automation solutions are designed to work harmoniously with various equipment, including robotic arms and mobile robots, creating a fully integrated ecosystem for laboratories. This collaboration is poised to enhance laboratory productivity and lower errors in experimental protocols, making drug discovery faster and more reliable.
Future Developments
The first versions of BD flow cytometry software that will be compatible with the Biosero automation system are expected to roll out for research use in the near future, specifically aimed at aiding institutions focused on innovative drug therapies. BD has committed to enhance their existing product lines, including the BD FACSymphony A1™ Cell Analyzer and the BD FACSLyric™ Flow Cytometry System, ensuring they align with cutting-edge automation technologies.
Meet BD's Commitment
BD, one of the foremost global medical technology companies, is dedicated to advancing health through innovation. With over 70,000 employees, BD focuses on improving diagnostics, medical discovery, and the efficacy of clinical procedures. Through collaboration and technology, they aim to meet the healthcare challenges of today and contribute to global health improvements.
About Biosero
Biosero, part of the BICO group, is committed to developing automation solutions that facilitate scientific research. Their Green Button Go® Scheduler software allows researchers to effectively manage laboratory workflows and operations, thereby boosting productivity. Biosero’s mission encompasses creating scalable automation solutions that are adaptable to the ever-changing landscape of drug discovery and development.
Frequently Asked Questions
What is the main goal of the BD and Biosero collaboration?
The collaboration focuses on integrating robotic automation with BD flow cytometry instruments to accelerate drug discovery and development processes.
How does flow cytometry contribute to drug discovery?
Flow cytometry allows researchers to analyze the effects of drug candidates on individual cells, facilitating drug candidate identification and validation throughout the development process.
What is Green Button Go® software?
It is a laboratory automation software developed by Biosero that enhances workflow efficiency by enabling integration with various lab instruments, including robotic systems.
When will the new software for BD flow cytometers be available?
The new versions compatible with Biosero's software are projected to be available for research use in the near future.
How does BD support global health issues?
BD partners with organizations worldwide to address public health challenges by advancing medical technology and improving healthcare delivery.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. If any of the material offered here is inaccurate, please contact us for corrections.